fingolimod hydrochloride has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 25 (75.76) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmadian, SR; Ghasemi-Kasman, M; Hashemian, M; Nosratiyan, N; Parsian, H; Rostami-Mansoor, S | 1 |
| Esfandiary, E; Ghanadian, M; Ghasemi, N; Moradi, V; Rashidi, B | 1 |
| Alasmari, AF; Alharbi, M; Alshammari, A; Assiri, MA; Kalfin, R; Kapoor, T; Kumar, N; Mehan, S; Narula, AS; Sharma, N; Suri, M | 1 |
| Beygtashkhani, R; Farbod, Y; Fatemi, R; Moghaddam, HF | 1 |
| Ghasemi-Kasman, M; Hashemian, M; Parsian, H; Sadeghi, F | 1 |
| Décard, BF; Derfuss, T; Diebold, M; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Tsagkas, C | 1 |
| Naser Moghadasi, A; Navardi, S; Sahraian, MA | 1 |
| Dargahi, L; Jorjani, M; Khodabakhsh, P; Mohaghegh Shalmani, L; Pournajaf, S; Valian, N | 1 |
| Oel, D; Rigler-Hohenwarter, K; Topakian, R; Trenkler, J | 1 |
| Dev, KK; O'Sullivan, SA; Velasco-Estevez, M | 1 |
| Hashimoto, Y; Kira, JI; Matsushita, T; Shinoda, K; Tanaka, E; Uehara, T; Yamasaki, R | 1 |
| AbuBaker, J; Al-Khairi, I; Al-Temaimi, R; Alroughani, R | 1 |
| Bielawski, J; Kim, S; Kong, Y; Li, J; Yang, H; Zhou, B | 1 |
| Chataway, J; Doshi, A | 1 |
| Ahn, SW; Cho, JY; Huh, SY; Hyun, JW; Kim, BJ; Kim, HJ; Kim, SH; Kim, W; Lee, SH; Park, MS | 1 |
| Balk, LJ; de Vries, HE; den Hoedt, S; Eijlers, AJC; Killestein, J; Leurs, CE; Lopes Pinheiro, MA; Mulder, MT; Schoonheim, MM; Uitdehaag, BMJ; Wierts, L | 1 |
| Erdem-Özdamar, S; Erdener, ŞE; Göçmen, R; Kurne, A; Nurlu, G | 1 |
| Dev, KK; Mir, AK; Pritchard, AJ | 1 |
| Blanc, CA; Lane, TE; Rosen, H | 1 |
| Amor, S; Beyer, C; Clarner, T; Kipp, M; Schmidt, T; Slowik, A | 1 |
| Alme, MN; Bø, L; Myhr, KM; Nystad, AE; Torkildsen, Ø; Vedeler, CA; Wergeland, S | 1 |
| Alroughani, R; Amato, MP; Barnett, M; Bergamaschi, R; Boz, C; Butzkueven, H; Cristiano, E; Duquette, P; Fernandez-Bolaños, R; Fiol, M; Girard, M; Grammond, P; Grand'Maison, F; Gray, O; Havrdova, E; Horakova, D; Hupperts, R; Iuliano, G; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kappos, L; Kister, I; Lechner-Scott, J; Lugaresi, A; Moore, F; Oreja-Guevara, C; Petersen, T; Petkovska-Boskova, T; Pucci, E; Saladino, ML; Shaw, C; Shuey, N; Slee, M; Spelman, T; Terzi, M; Trojano, M; Van Pesch, V; Verheul, F; Warrender-Sparkes, M; Young, C | 1 |
| Dev, KK; O'Sullivan, C | 1 |
| Blanc, CA; Grist, JJ; Lane, TE; Rosen, H; Sears-Kraxberger, I; Steward, O | 1 |
| Baharvand, H; Javan, M; Yazdi, A | 1 |
| Balatoni, B; Baumruker, T; Bornancin, F; Foster, CA; Howard, LM; Kinnunen, A; Mechtcheriakova, D; Sobanov, J; Storch, MK; Wlachos, A | 1 |
| Antel, JP; Darlington, PJ; Jarjour, AA; Kennedy, TE; Ludwin, SK; Miron, VE; Soliven, B | 1 |
| Antel, JP; Dukala, D; Kim, HJ; Ludwin, SK; Miron, VE; Proia, RL; Soliven, B; Traka, M | 1 |
| Fujita, T; Kohno, T; Tsuji, T; Yoshida, Y | 1 |
| Baker, D; Giovannoni, G; Jackson, SJ | 1 |
| Apicco, D; Guckian, K; Hu, Y; Ji, B; Lee, X; Mi, S; Miller, RH; Pepinsky, RB | 1 |
| Dev, KK; Sheridan, GK | 1 |
| Lassmann, H | 1 |
1 review(s) available for fingolimod hydrochloride and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Multiple sclerosis, a treatable disease .
Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines | 2017 |
32 other study(ies) available for fingolimod hydrochloride and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Intranasal administration of fingolimod (FTY720) attenuates demyelination area in lysolecithin-induced demyelination model of rat optic chiasm.
Topics: Administration, Intranasal; Animals; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophosphatidylcholines; Male; Optic Chiasm; Rats; Rats, Wistar | 2022 |
The effect of Zingiber Officinale Extract on Preventing Demyelination of Corpus Callosum in a Rat Model of Multiple Sclerosis
Topics: Animals; Anti-Inflammatory Agents; Corpus Callosum; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin Sheath; Rats; Rats, Wistar; Zingiber officinale | 2022 |
Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis.
Topics: Adenylyl Cyclases; Animals; Colforsin; Cytokines; Demyelinating Diseases; Donepezil; Ethidium; Fingolimod Hydrochloride; Gliotoxin; Memantine; Multiple Sclerosis; Myelin Basic Protein; Myelin Sheath; Nerve Growth Factors; Neurodegenerative Diseases; Oligodendroglia; Rats; Rats, Wistar; Simvastatin | 2022 |
Effects of Crocin on brain neurotrophins, cognition, balance and pain in toxic-induced demyelination model.
Topics: Animals; Brain; Cognition; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Nerve Growth Factors; Pain; Rats; Rats, Wistar | 2024 |
Fingolimod (FTY720) improves the functional recovery and myelin preservation of the optic pathway in focal demyelination model of rat optic chiasm.
Topics: Animals; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Histone Deacetylase 1; Lysophosphatidylcholines; Male; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Optic Chiasm; Rats; Rats, Wistar; Recovery of Function; Remyelination; Sphingosine-1-Phosphate Receptors; Valproic Acid | 2019 |
Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.
Topics: Administration, Oral; Adult; Chemical and Drug Induced Liver Injury; Demyelinating Diseases; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Hepatitis E; Hepatitis E virus; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2019 |
Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report.
Topics: Adult; Demyelinating Diseases; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Rituximab | 2020 |
Fingolimod increases oligodendrocytes markers expression in epidermal neural crest stem cells.
Topics: Animals; Biomarkers; Cell Survival; Demyelinating Diseases; Dose-Response Relationship, Drug; Epidermis; Fingolimod Hydrochloride; Hair Follicle; Male; Nerve Growth Factors; Neural Crest; Neural Stem Cells; Oligodendroglia; Rats; Rats, Wistar; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy?
Topics: Adult; Cytomegalovirus Infections; Demyelinating Diseases; Encephalitis, Viral; Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Male; Sphingosine 1 Phosphate Receptor Modulators | 2021 |
Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors.
Topics: Animals; Animals, Newborn; Astrocytes; Brain; Calcium-Binding Proteins; Cells, Cultured; Cerebellum; Demyelinating Diseases; DNA-Binding Proteins; Female; Fetus; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Hydrogen Peroxide; Immunosuppressive Agents; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Myelin-Oligodendrocyte Glycoprotein; Neurofilament Proteins; Oxidative Stress; Receptors, Lysosphingolipid; Repressor Proteins; Zebrafish Proteins | 2017 |
Re-emergence of a tumefactive demyelinating lesion after initiation of fingolimod therapy.
Topics: Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Neuroimaging | 2017 |
Remyelination modulators in multiple sclerosis patients.
Topics: Adult; Biomarkers; Brain-Derived Neurotrophic Factor; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Insulin-Like Growth Factor Binding Protein 1; Lipocalin-2; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Neurofilament Proteins; Remyelination; Sex Characteristics | 2017 |
Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination.
Topics: Animals; Apoptosis; Brain; Chimera; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Gene Expression; Gliosis; Indans; Inflammation; Male; Mice, Inbred C57BL; Mice, Transgenic; Neuroglia; Neuroprotective Agents; Oxadiazoles; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; White Matter | 2018 |
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Topics: Adolescent; Adult; Crotonates; Demyelinating Diseases; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Nitriles; Oligoclonal Bands; Optic Neuritis; Quinolones; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Time Factors; Toluidines; Young Adult | 2019 |
Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis.
Topics: Adult; Biomarkers; Ceramides; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Longitudinal Studies; Male; Prospective Studies; Sphingomyelin Phosphodiesterase; Sphingomyelins; Treatment Outcome | 2019 |
Remission with fingolimod in a case of demyelinating polyneuropathy.
Topics: Adolescent; Demyelinating Diseases; Electric Stimulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Neural Conduction; Polyneuropathies; Propylene Glycols; Sphingosine | 2014 |
Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.
Topics: Animals; Cerebellum; Coculture Techniques; Cytokines; Demyelinating Diseases; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation Mediators; Mice; Mice, Transgenic; Myelin-Oligodendrocyte Glycoprotein; Phenotype; Propylene Glycols; Sphingosine; Spleen; T-Lymphocytes; Tissue Culture Techniques | 2014 |
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Central Nervous System; Demyelinating Diseases; Disease Models, Animal; Encephalitis, Viral; Fingolimod Hydrochloride; Green Fluorescent Proteins; Immunosuppressive Agents; Lymph Nodes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Murine hepatitis virus; Nerve Tissue Proteins; Propylene Glycols; Severity of Illness Index; Sphingosine; T-Lymphocytes, Cytotoxic; Virus Replication | 2014 |
The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination.
Topics: Amyloid beta-Protein Precursor; Animals; Corpus Callosum; Cuprizone; Demyelinating Diseases; Fingolimod Hydrochloride; Gene Expression Regulation; Liver; Male; Membrane Proteins; Mice, Inbred C57BL; Neuroprotective Agents; Phosphatidate Phosphatase; Phosphoric Monoester Hydrolases; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2015 |
Fingolimod does not enhance cerebellar remyelination in the cuprizone model.
Topics: Animals; Cerebellum; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine | 2015 |
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Topics: Administration, Oral; Adult; Aged; Demyelinating Diseases; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Galactosylsphingosine (psychosine)-induced demyelination is attenuated by sphingosine 1-phosphate signalling.
Topics: Animals; Apoptosis; Astrocytes; Demyelinating Diseases; Fingolimod Hydrochloride; Humans; Leukodystrophy, Globoid Cell; Lipopolysaccharides; Lysophospholipids; Mice; Microscopy, Fluorescence; Psychosine; Rats; Signal Transduction; Sphingosine | 2015 |
Sphingosine-1-phosphate receptor antagonism enhances proliferation and migration of engrafted neural progenitor cells in a model of viral-induced demyelination.
Topics: Animals; Axons; Cell Differentiation; Cell Movement; Cells, Cultured; Central Nervous System; Demyelinating Diseases; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice, Transgenic; Mitogen-Activated Protein Kinases; Multiple Sclerosis; Murine hepatitis virus; Neural Stem Cells; Oligodendroglia; Receptors, Lysosphingolipid | 2015 |
Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720).
Topics: Animals; Corpus Callosum; Demyelinating Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophosphatidylcholines; Male; Mice, Inbred C57BL; Myelin Sheath; Neural Stem Cells; Neuroprotective Agents; Oligodendroglia | 2015 |
FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.
Topics: Animals; Antigens; Blood-Brain Barrier; Blotting, Western; Brain; Capillary Permeability; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunization; Immunosuppressive Agents; Myelin Proteins; Phospholipases A2, Cytosolic; Polymerase Chain Reaction; Propylene Glycols; Random Allocation; Rats; Sphingosine; Spinal Cord | 2009 |
Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
Topics: Animals; Animals, Newborn; Astrocytes; Cerebellum; Demyelinating Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophosphatidylcholines; Mice; Microglia; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stem Cells; Tissue Culture Techniques | 2010 |
Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.
Topics: Animals; Axons; Blotting, Western; Corpus Callosum; Cuprizone; Demyelinating Diseases; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Electron; Myelin Sheath; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine | 2011 |
Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
Topics: Animals; Autoantigens; Cyclosporine; Demyelinating Diseases; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Glycoproteins; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Nerve Tissue Proteins; Peptide Fragments; Propylene Glycols; Remission Induction; Secondary Prevention; Specific Pathogen-Free Organisms; Sphingosine; Spinal Cord | 2011 |
Fingolimod modulates microglial activation to augment markers of remyelination.
Topics: Animals; Biomarkers; Cell Culture Techniques; Cells, Cultured; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophosphatidylcholines; Microglia; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Myelin Sheath; Nerve Degeneration; Pregnancy; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Spheroids, Cellular; Sphingosine | 2011 |
Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
Topics: Animals; Chelating Agents; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Myelin Sheath; Nerve Regeneration; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine | 2011 |
S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures.
Topics: Animals; Animals, Newborn; Astrocytes; Cell Movement; Cerebellum; Chemokine CCL20; Chemokine CCL3; Chemokines; Demyelinating Diseases; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Lysophosphatidylcholines; Myelin Basic Protein; Neurofilament Proteins; Organ Culture Techniques; Oxadiazoles; Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Thiophenes | 2012 |
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Topics: Animals; Astrocytes; Blood-Brain Barrier; Ceramides; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; NF-kappa B; Oligodendroglia; Propylene Glycols; Quinolones; Sphingosine | 2012 |